Publication:
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta

dc.contributor.authorHeidrich, Benjamin
dc.contributor.authorYurdaydin, Cihan
dc.contributor.authorKabacam, Gokhan
dc.contributor.authorRatsch, Boris A.
dc.contributor.authorZachou, Kalliopi
dc.contributor.authorBremer, Birgit
dc.contributor.authorDalekos, George N.
dc.contributor.authorErhardt, Andreas
dc.contributor.authorTabak, Fehmi
dc.contributor.authorYalçın, Kendal
dc.contributor.authorGürel, Selim
dc.contributor.authorZeuzem, Stefan
dc.contributor.authorCornberg, Markus
dc.contributor.authorBock, C. -Thomas
dc.contributor.authorManns, Michael P.
dc.contributor.authorWedemeyer, Heiner
dc.contributor.buuauthorGÜREL, SELİM
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentGastroenteroloji Ana Bilim Dalı
dc.contributor.researcheridHLH-8209-2023
dc.date.accessioned2024-08-15T11:10:34Z
dc.date.available2024-08-15T11:10:34Z
dc.date.issued2014-07-01
dc.description.abstractInterferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. However, the clinical and virological long-term outcome of HDV-infected patients treated with PEG-IFNa is unknown. We performed a retrospective-prospective follow-up of 77 patients treated for 48 weeks with either PEG-alfa-2a and adefovir (ADV) or either drug alone in the Hep-Net-International-Delta-Hepatitis-Intervention-Study 1 (HIDIT-1) trial. Long-term follow-up data were available for 58 out of 77 patients (75%) with a median time of follow-up of 4.5 (0.5-5.5) years and a median 3 visits per patient. Patients treated with ADV alone received retreatment with PEG-IFNa (48% versus 19%; P = 0.02) more often. Hepatitis B virus surface antigen (HBsAg) became negative in six PEG-IFNa-treated patients until the end of long-term follow-up (10%). Sixteen patients tested HDV RNA-negative 6 months after PEG-IFNa treatment who were entered in the long-term follow-up study. Out of these, nine individuals tested HDV RNA-positive at least once during further long-term follow-up, with seven patients being HDV RNA-positive at the most recent visit. Clinical endpoints (liver-related death, liver transplantation, hepatic decompensation, hepatocellular carcinoma) were observed in three PEG-IFNa-treated (8%) and three ADV-treated (14%) patients during posttreatment long-term follow-up with an overall annual event rate of 2.5% (4.9% in cirrhosis). Sequencing confirmed the reappearance of pretreatment virus strains in all cases. Conclusion: Late HDV RNA relapses may occur after PEG-IFNa therapy of hepatitis delta and thus the term sustained virological response should be avoided in HDV infection. The annual posttreatment rate of clinical events in hepatitis delta patients eligible for PEG-IFNa therapy is about 2.5% and 4.9% in patients with cirrhosis.
dc.description.sponsorshipHep-Net Study House
dc.description.sponsorshipGerman Liver Foundation
dc.description.sponsorshipHepNet e.V.
dc.description.sponsorshipIntegrated Research and Treatment Center Transplantation (IFB-Tx Project 37) 01EO0802
dc.description.sponsorshipHannover Medical School
dc.description.sponsorshipGerman Centre for Infection Research ("DZIF")
dc.identifier.doi10.1002/hep.27102
dc.identifier.endpage97
dc.identifier.issn0270-9139
dc.identifier.issue1
dc.identifier.startpage87
dc.identifier.urihttps://doi.org/10.1002/hep.27102
dc.identifier.urihttps://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.27102
dc.identifier.urihttps://hdl.handle.net/11452/44067
dc.identifier.volume60
dc.identifier.wos000337969000014
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.journalHepatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectB-virus
dc.subjectNatural-history
dc.subjectPlus adefovir
dc.subjectInterferon
dc.subjectResolution
dc.subjectRibavirin
dc.subjectPatterns
dc.subjectDecline
dc.subjectGastroenterology & hepatology
dc.titleLate HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Gastroenteroloji Ana Bilim Dalı
relation.isAuthorOfPublicationd7a9ea11-69fc-4122-a365-8fb2123512e6
relation.isAuthorOfPublication.latestForDiscoveryd7a9ea11-69fc-4122-a365-8fb2123512e6

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Gurel_vd_2014.pdf
Size:
740.93 KB
Format:
Adobe Portable Document Format

Collections